Abstract
Introduction
Bioresorbable vascular scaffolds (BVS) have been designed to improve the limitations of conventional percutaneous coronary intervention (PCI) with drug-eluting stents (DES), namely to restore vessel vasomotion and to minimize neoarteriosclerosis [1] . The everolimus-eluting BVS (EE-BVS, Abbott Vascular, Santa Clara, USA) has been studied in randomized trials compared to EE-DES. Although initial data suggested noninferiority at 12-months [1] , the latest registries and meta-analysis found an increased risk of BVS--thrombosis [2] [3] [4] [5] . Suboptimal BVS-implantation resulting in BVS-underexpansion and malapposition was suggested to be causal [6] [7] [8] . Guidance by intravascular imaging in sizing and optimising BVS-implantation is hypothesized to solve these issues. A BVS specific implantation protocol including lesion preparation, accurate vessel sizing and mandatory post-dilation was implemented after the first observations of scaffold thrombosis when the device first came into use in routine PCI in Germany back in 2013 [6, 9] . Intravascular imaging with optical coherence tomography (OCT) is considered to allow optimal BVS-size selection, strut apposition and BVS-expansion [6] . Recently published data found OCT to detect BVS-malapposition and underexpansion despite angiographic determined success in over 25% of implantations [10] . Furthermore, preliminary findings of OCT-based guidance for DES-implantation have been shown to improve clinical outcomes [11] . Aside from guidance during PCI, OCT has become a powerful tool to evaluate DES and BVS--coverage and apposition in follow-up examinations. Quantitative data from follow-up OCT-imaging has been proposed as surrogate parameters for stent performance linked to clinical outcome [12] [13] [14] [15] [16] . The present ALSTER-OCT ABSORB registry (AskLepios ST. GEoRg's hospital-Optical Coherence Tomography for follow-up of ABSORBable vascular scaffolds) analyzed OCT-data regarding BVS-coverage, neointimal thickness and apposition at 6 months following EE-BVS-implantation. These data were linked to implantation technique (angiography-guided vs. OCT-guided) and 2-year clinical outcome.
Methods

Design and patient enrolment
The ALSTER-OCT ABSORB registry ( Fig. 1 ) was a prospective, all-comers, single-center registry to study EE-BVS healing characteristics by OCT at 6 months subsequent to implantation. Results were stratified for implantation technique regarding OCT-vs. angiography-guided EE-BVS--implantation. The registry also tried to identify EE-BVS-healing patterns that would have possibly allowed to predict 2-year clinical outcome. Between 01/2014 and 09/2015 surveillance angiography with OCT was performed in 29 patients. Patients with complex lesions (ostial stenosis, stenosis of the left main trunk, lesions ≥ 10 mm length in vessels ≤ 3.5 mm diameter) treated with EE-BVS were eligible. The lesion type assessments were performed according to latest ACC/AHA definitions [17] . This registry conforms to the guiding principles of the Declaration of Helsinki of 2008 and was approved by the local institutional review board. Written informed consent was obtained from all patients.
PCI and BVS implantation
All interventions and choice of antithrombotic therapy was performed according to current PCI guidelines [18] . Intravenous heparin 100 IU/kg was given to maintain the activated clotting time > 250 s. Balloon predilation was performed in all patients. BVS-implantation at a pressure not exceeding the burst pressure rate was mandatory. If post-dilation was performed, a non-compliant balloon was used. Angiographic success was defined as diameter stenosis < 30% with thrombolysis in myocardial infarction (TIMI) 3 flow by visual assessment [10] . After evidence of angiographic success no further evaluation was performed in the first 17 consecutive patients (group 1: angiography-guided EE--BVS-implantation).
Periprocedural OCT-imaging
In patients of group 2 (OCT-guided EE-BVS--implantation) initial predilatation was performed to allow OCT-imaging of the lesions, to determine proximal and distal reference diameters, position of side branches, and further lesion characteristics. Further predilatation was undertaken to within 0.5 mm of the reference vessel diameter. The average diameter of the target zone lumen was determined as reference for the BVS diameter. If BVS-underexpansion or malapposition was identified by angiography, further post-dilatation was undertaken using non-compliant balloons until angiographic success was achieved. A further OCT--analysis was performed afterwards to assess BVS--expansion, apposition and dissection. On the basis of this OCT-analysis, further BVS-optimisation was performed according to the following definitions: BVS-underexpansion was defined as minimum BVS area < 80% of the mean proximal and distal reference lumen areas [10] . BVS-malapposition was defined as incomplete BVS-apposition area delineated by the abluminal side of the frame border of the malapposed strut and the endoluminal contour of the vessel wall [10, 19] . A representative case is presented in Figure 2 . 
OCT-imaging and analysis at follow-up
Frequency domain OCT-pullbacks were performed according to guidelines and obtained with the Ilumien system (St. Jude Medical, Saint Paul, USA) [13, 14, 20, 21] . As recently described acquired data was analyzed at the LightLab Imaging OCT-offline workstation (OCT-system software B.0.1, LightLab) [13, 14] . Image assessments were performed in every 5 th cross-section. All crosssections were screened for quality and excluded from analysis if any portion of the image off of the screen, the image was of poor quality caused by residual blood, sew-up artefact, or reverberation. Struts located at the ostium of coronary artery side branches, are donated as non-apposed sidebranch struts and exclude from the analysis. According to previously described methods BVS were analyzed strut-by-strut and qualified as the following: Embedded covered struts: covered by tissue with at least 50% of the strut boundary below the level of the luminal surface. Protruding covered struts: covered by tissue and with the strut boundary located above the level of the luminal surface. Uncovered apposed struts: for those not covered by tissue but abutting the vessel wall and final uncovered and malapposed struts: for those not covered by tissue and not abutting the vessel wall. If neointimal tissue was observed, its average thickness was measured. It was measured in every strut between abluminal site of the strut core and the lumen. Since the strut thickness of EE-BVS is 150 μm, the strut was considered as covered whenever the thickness of the coverage was above this threshold value [19, 22, 23] . The strut core area was measured within the area of the strut. Two independent expert observers (blinded to the clinical and procedural characteristics) did the OCT-analysis. To determine reproducibility, measurements of 5 randomly chosen patients (n = 631 struts) were repeated and intra-and inter-observer reproducibility were calculated [12] .
Clinical follow-up
Target-lesion-failure was defined as a composite of cardiac death, target-vessel myocardial infarction (MI), ischemia driven target-lesion-revascularization (TLR) within 2 years [13, 14, 24] . Target-vessel-revascularisation (TVR) was defined as non-target lesion revascularization of the target vessel [13, 14, 25] . The composite of cardiac death, MI and ischemia driven TLR within 2 years was considered as major adverse cardiac events [13, 14, 26] . 
Statistical analysis
Continuous data were summarised as means and standard deviations or as medians and 25 th and 75 th percentiles, as appropriate. Categorical data are presented as number (percentage). To account for the clustered nature of OCT-data, multilevel regression analyses on lesion level, cross-section level and strut level were realised [13, 14, 27] . For intra-group analysis within each group, an analysis of variance was performed. A p-value < 0.05 was considered to be statistically significant and all analyses were two-tailed. Intra-observer and interobserver reproducibility was assessed using the intraclass correlation coefficient. Statistical analysis was performed using GraphPad Prism, version 6 (GraphPad Software, Inc., San Diego, CA, USA).
Results
Patient baseline characteristics
A total of 29 patients with 31 lesions and 40 BVSs were analyzed. Figure 1 is depicting the flow chart of the registry. Table 1 summarizes baseline patient characteristics and procedural details. No differences were found between the groups. C. Angiography at 6 months follow-up; D, E, F. OCT images at baseline after BVS implantation with perfect BVS apposition from distal to proximal; G, H, I. OCT images after 6 months with covered apposed BVS struts from distal to proximal; LAD -left anterior descending artery.
Procedural characteristics
Lesion preparation using predilation was performed in all patients. In the first 17 consecutive patients (19 lesions) no OCT-based pre-interventional sizing was conducted. Only angiography was used to determine success after BVS-implantation. (Fig. 2) . OCT detected no tissue prolapse or dissection, yet in 3/14 (21.4%) of lesions a BVS-underexpansion (1/14, 7.1%) or malapposition (2/14, 14.2%) was observed and further BVS-optimisation was performed as described above.
OCT-analyses
Neither at lesion level, cross-section level or strut level were any differences found concerning coverage or apposition between the groups ( Table 2 ). The qualitative assessment was highly reproducible and comparable to findings of other groups: the intra-observer and inter-observer reproducibility (R 2 ) were 0.86 and 0.83, respectively [28] . Mean neointimal area was significantly higher in the angio-guided group.
Clinical follow-up
Patient clinical follow-up is shown in Table 3 . Due to two patients (#1/#2) with BVS-thrombosis there were two target-lesion failure in group 1 and none in group 2. ST-segment elevation myocardial infarction (STEMI) due to BVS-thrombosis occurred after 9 months in patient #1 while the patient was on dual antiplatelet therapy (DAPT) with acetylsalicylic acid and clopidogrel. The patient was judged to be drug-compliant by the treating physician. Retrospectively, the OCT-analysis at 6-months showed no strut uncoverage or malapposition. The reason for BVS-thrombosis therefore remains elusive in this patient. The patient survived the STEMI with a left ventricular ejection fraction of 39%.
Patient #2 experienced a BVS-thrombosis with STEMI 18 months after EE-BVS-implantation. In retrospect, OCT-analysis at 6-months in patient #2 showed partial uncoverage and malapposition of the EE-BVS (23.6% uncovered apposed struts and 1.9% uncovered malapposed struts). As the patient had no symptoms of angina and the angiographic picture was unremarkable the decision was made not to perform any treatment based on experience with current generation DES. DAPT was prescribed for a total of 12 months. 18 months after EE-BVS-implantation the patient was readmitted with STEMI due to acute BVS--thrombosis. OCT at this time showed insufficient wall apposition in the distal part of the BVS with subsequent incomplete coverage with neointimal tissue as potential cause for the BVS-thrombosis (Fig. 3) [29] . The patient survived the STEMI with a normal ejection fraction.
Discussion
This registry describes unremarkable OCT-data at 6-month follow-up of EE-BVS treated patients. Scaffold struts had neointima coverage and strut malapposition rates similar to current generation DES [13] . As BVS have the same everolimus coating as EE-DES, this finding comes as no surprise. Yet the latest data found EE-BVS to be associated with a higher risk of BVS-thrombosis compared to EE-DES [7] . In detail the ABSORB III study found an increase in clinical events at 2-year with EE-BVS compared to EE-DES [3] . Additionally 2-year results from the Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial (AIDA) showed that the use of EE-BVS is associated with an increased risk of BVS-thrombosis and of target-vessel MI, compared with patients who received an EE-DES [5] . These findings have led to a warning letter to physicians by the Food and Drug Administration and a stop to routine implants. The future of ABSORB technology is therefore quite uncertain at the moment.
The causes of BVS-thrombosis have yet to be fully elucidated [8] . A recent meta-analysis focusing on possible mechanical causes of BVSthrombosis utilizing intracoronary imaging found malapposition, incomplete lesion coverage, and underdeployment are frequently observed in cases of early BVS-thrombosis, whereas, malapposition, late discontinuity and peri-strut low-intensity area are the predominant factors in late BVS-thrombosis [8] . Repeatedly improved implantation techniques has been hypothesized to allow for better clinical outcomes [7] .
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In this series, no early BVS-thrombosis was observed. This finding is reassuring proving correct patient selection and improved implantation techniques were rolled out in Germany following early observations of BVS-thrombosis back in 2012 and 2013. However, even OCT-analysis at 6-months had previously shown subtle differences of stent healing and was detected even with low patient numbers and did not detect any substantial differences between OCT-guided implantation vs.
angio-guided implantation, not even as a trend [13] . Even larger patient numbers are therefore was unlikely to reveal a different result. These data confirm the current implantation techniques including lesion preparation, sizing and mandatory post-dilatation with a non-compliant balloon leads to good short-term results. In addition, the absolute values of neointima coverage and strut malapposition are very similar to current generation DES at 6-months [13] . Surprisingly OCT at 6-months was unable to define patients at risk for BVS-thrombosis based on the characteristics of strut malapposition and/ /or neointima growth. The two patients that developed BVS-thrombosis at 9 and 18-months had BVS-healing patterns not much different from the rest of the cohort. Discontinuation of DAPT is an important cause of BVS-thrombosis [7] , yet the patient was deemed to be compliant and DAPT can be stopped as early as 3-months after DES--implantation without any increased risk of stentthrombosis.
The OCT-analyses of the 2 cases of BVS--thrombosis were inconsistent. While the first patient had a really unremarkable finding of BVS-healing with almost complete coverage at 6-months, the second patient had malapposed struts partially covered with neointima at the distal end due to an enlargement of the vessel at that particular site. This is seen regularly with current generation DES and is left untreated without consequences [13] . Apparently BVS is less forgiving in this instance yet treatment options are limited if the vessel has various diameters like in this case; the only available option is to prolong DAPT beyond 1 year and most likely until the BVS is completely resorbed which would result in DAPT to be necessary for 3 years. A recent study found no case of very late BVS-thrombosis in patients who continued on DAPT for > 18 months [30] . Although prolongation of DAPT may prevent BVS-thrombosis, the rate of bleeding events are a matter of concern.
So apparently, improved implantation techniques are unlikely to resolve the issues around BVS late clinical events. Another speculation would be that the BVS-polylactite material may have a late prothrombotic or platelet activation property during resorbing which is not sufficiently understood in the human environment. While there are no such data available the observation from this small cohort, as well as from the recently presented AIDA trial which had a much larger cohort of patients, it was also unable to link implantation technique or any other variable to late BVS-thrombosis suggests other factors could be involved than those currently under discussion [5] .
The 3-year data of ABSORB-China and ABSORB-Japan found no increased rate of BVS--thrombosis. An optimal implantation technique was suggested to be responsible for these findings [31, 32] . Yet the AIDA trial did not support this hypothesis [5] . Aggressive post-dilation may trigger endothelial growth. While all angiography-guided BVS were postdilated, the OCT-guided group only received postdilatation in 21.4% of cases. In this context it is quite a striking follow-up, OCT found increased neointimal growth reaching a similar thickness compared to data observed with DES in the angio-guided group which is possibly linked to aggressive post-dilation [13] . The data are presented as number of events (n) and percentage of total number (%).
Christian-Hendrik Heeger et al., OCT vs. angiography guidance during scaffold PCI Lesion preparation and post-dilatation with non-compliant balloons has been suggested to improve EE-BVS implantation results [7] . Mandatory post-dilatation was thought to improve implantation outcomes; the OCT-guided data presented here find OCT-guided intervention to lead to comparably good results. Vice versa, angio-guided implantation with mandator post-dilatation has similar results than OCT-guided BVS-implantation. Yet this optimization appears not to prevent BVS-thrombosis. The reasons for this are unclear and apparently needs to be identified prior to further routine use of EE-BVS. The fact that BVS-thrombosis did occur despite BVS-coverage similar to EE-DES leads to the hypothesis that either strut thickness or the BVS-material could be the issue leading to these late events. The issue that the underlying material and resorption may activate platelet adhesion should be investigated and addressed including other materials like magnesium, which should be further studied.
Limitations of the study
The fact that no randomization was performed is limiting in the conclusions reached. A further limitation is the limited number of patients and the differring sample size of the two groups. The number of patients is certainly too small to draw definitive conclusions about clinical outcomes, yet OCT-assessment of BVS-apposition and coverage correlates to clinical outcomes [12] [13] [14] [15] .
Conclusions
This registry found almost 90% of BVS-struts to be covered with neointima at 6 months. Both angiography-and OCT-guided EE-BVS-implantation had favourable 6-month results based on OCT-data. Yet OCT-analyses at 6-months were not able to predict late clinical events as there were in this study with 2 BVS-thrombosis occurring 9 and 18 months following BVS-implantation.
